AptaBio Therapeutics Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-16,440	-12,062	-10,565
Depreciation & Amortization	539.93	539.11	484.62
Loss (Gain) From Sale of Investments	766.12	244.29	2,494
Loss (Gain) on Equity Investments	300.78	4.19	-
Stock-Based Compensation	227.13	186.65	123.6
Other Operating Activities	1,855	-2,458	631.31
Change in Other Net Operating Assets	-1,935	-549.77	-1.91
Operating Cash Flow	-15,761	-14,095	-6,833
Capital Expenditures	-1,242	-1,345	-1,041
Sale (Purchase) of Intangibles	-46.6	-46.6	-10.36
Investment in Securities	-436.78	-9,006	5,332
Other Investing Activities	42.24	60.15	27.66
Investing Cash Flow	-2,055	-12,737	1,743
Long-Term Debt Issued	-	38,900	-
Long-Term Debt Repaid	-	-127.85	-87.95
Net Debt Issued (Repaid)	38,769	38,772	-87.95
Issuance of Common Stock	-	-	589.2
Other Financing Activities	-18.7	-19.2	-5.24
Financing Cash Flow	49,852	49,854	496.01
Foreign Exchange Rate Adjustments	19.47	5.07	16.76
Miscellaneous Cash Flow Adjustments	-	-0	0
Net Cash Flow	32,056	23,027	-4,577
Free Cash Flow	-17,003	-15,440	-7,874
Free Cash Flow Margin	-827.33%	-4767.39%	-16284.04%
Free Cash Flow Per Share	-762.50	-692.42	-353.27
Cash Interest Paid	10.98	11.47	4.49
Cash Income Tax Paid	98.04	48.45	-34.01
Levered Free Cash Flow	-	-13,398	-
Unlevered Free Cash Flow	-	-12,659	-
Change in Net Working Capital	-	1,429	-

Source: S&P Capital IQ. Standard template. Financial Sources.